Phyllis Arthur's Testimony to Senate HELP Committee on Lessons Learned from Covid-19
July 27, 2021
COVID-19 will not be our last public health emergency. We face numerous bio-threats from natural and bioterror threats. Strong support for medical countermeasures R&D is critical to protecting our national security.
Today I will share BIO’s thoughts on how to strengthen our national preparedness through coordinated leadership, expanded partnership with industry and better public health infrastructure.
Dear Colleagues,This month marks my one-year anniversary as BIO’s CEO. Like most of us in biotech, this post has been a labor of love. At no time in my 25-year career in this industry have I ever witnessed such awe-inspiring science. Today, we…
Re: BIO Comments on Office of Management and Budget (OMB) Statistical Policy Directive No. 8 North American Industry Classification System (NAICS)-Request forComments on Possible Revisions for 2027 (USBC–2024–0032)Dear Ms. Orvis,The Biotechnology…
Under the 340B program, participating manufacturers must offer 340B pricing on their covered outpatient drugs by covered entities, as a condition of having those drugs federally payable under Medicare Part B and Medicaid. Critically, Congress…
COVID-19 will not be our last public health emergency. We face numerous bio-threats from natural and bioterror threats. Strong support for medical countermeasures R&D is critical to protecting our national security.
Today I will share BIO’s thoughts on how to strengthen our national preparedness through coordinated leadership, expanded partnership with industry and better public health infrastructure.